APTO - アポト―ス・バイオサイエンシズ (Aptose Biosciences Inc.)

APTOのニュース

   FDA Grants Fast Track designation To Aptose Biosciences for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation  2022/05/04 12:41:58 Benzinga
Aptose Biosciences Inc. (NASDAQ: APTO ) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation. HM43239 is being investigated in an ongoing international Phase 1/2 … Full story available on Benzinga.com
   Aptose Biosciences Q4 2021 Earnings Preview (NASDAQ:APTO)  2022/03/21 21:35:43 Seeking Alpha
Aptose Biosciences (APTO) is scheduled to announce Q4 earnings results on Tuesday, March 22nd, after market close.The consensus EPS Estimate is -$0.17Over the last 3 months, EPS…
   Aptose to Present at Oppenheimer''s 32nd Annual Healthcare Conference  2022/03/01 12:30:00 Benzinga
SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO , TSX: APS ), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer''s 32 nd Annual Healthcare Conference: Aptose Presentation - Oppenheimer''s 32nd Annual Healthcare Conference Date: Tuesday, March 15, 2022 Time: 10:00 … Full story available on Benzinga.com
   Aptose Biosciences (APTO) Investor Presentation - Slideshow  2022/01/11 19:19:31 Seeking Alpha
   Aptose Biosciences Inc Shares Close the Day 12.6% Higher - Daily Wrap  2022/01/04 10:48:15 Kwhen Finance
Aptose Biosciences Inc (APTO) shares closed today 12.6% higher than it did at the end of yesterday. The stock is currently up 12.6% year-to-date, down 65.3% over the past 12 months, and up 12.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $1.55 and as low as $1.30 this week.Shares closed 78.9% below its 52-week high and 40.7% above its 52-week low.Trading volume this week was 3.6% higher than the 10-day average and 56.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 115.4% The company's stock price performance over the past 12 months lags the peer average by -4010.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Aptose Biosciences Q4 2021 Earnings Preview (NASDAQ:APTO)  2022/03/21 21:35:43 Seeking Alpha
Aptose Biosciences (APTO) is scheduled to announce Q4 earnings results on Tuesday, March 22nd, after market close.The consensus EPS Estimate is -$0.17Over the last 3 months, EPS…
   Aptose to Present at Oppenheimer''s 32nd Annual Healthcare Conference  2022/03/01 12:30:00 Benzinga
SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO , TSX: APS ), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer''s 32 nd Annual Healthcare Conference: Aptose Presentation - Oppenheimer''s 32nd Annual Healthcare Conference Date: Tuesday, March 15, 2022 Time: 10:00 … Full story available on Benzinga.com
   Aptose Biosciences (APTO) Investor Presentation - Slideshow  2022/01/11 19:19:31 Seeking Alpha
   Aptose Biosciences Inc Shares Close the Day 12.6% Higher - Daily Wrap  2022/01/04 10:48:15 Kwhen Finance
Aptose Biosciences Inc (APTO) shares closed today 12.6% higher than it did at the end of yesterday. The stock is currently up 12.6% year-to-date, down 65.3% over the past 12 months, and up 12.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $1.55 and as low as $1.30 this week.Shares closed 78.9% below its 52-week high and 40.7% above its 52-week low.Trading volume this week was 3.6% higher than the 10-day average and 56.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 115.4% The company's stock price performance over the past 12 months lags the peer average by -4010.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Aptose Biosciences Climbs 17% to Reclaim Some Losses  2021/12/16 16:57:58 The Motley Fool Canada
Aptose Biosciences (TSX:APS)(NASDAQ:APTO) recovered 17% after losing 45% this week from results of its drug trial gave investors a wait-and-see report. The post Aptose Biosciences Climbs 17% to Reclaim Some Losses appeared first on The Motley Fool Canada .
   Aptose Biosciences (APTO) Investor Presentation - Slideshow  2022/01/11 19:19:31 Seeking Alpha
   Aptose Biosciences Inc Shares Close the Day 12.6% Higher - Daily Wrap  2022/01/04 10:48:15 Kwhen Finance
Aptose Biosciences Inc (APTO) shares closed today 12.6% higher than it did at the end of yesterday. The stock is currently up 12.6% year-to-date, down 65.3% over the past 12 months, and up 12.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $1.55 and as low as $1.30 this week.Shares closed 78.9% below its 52-week high and 40.7% above its 52-week low.Trading volume this week was 3.6% higher than the 10-day average and 56.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 115.4% The company's stock price performance over the past 12 months lags the peer average by -4010.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Aptose Biosciences Climbs 17% to Reclaim Some Losses  2021/12/16 16:57:58 The Motley Fool Canada
Aptose Biosciences (TSX:APS)(NASDAQ:APTO) recovered 17% after losing 45% this week from results of its drug trial gave investors a wait-and-see report. The post Aptose Biosciences Climbs 17% to Reclaim Some Losses appeared first on The Motley Fool Canada .
   William G. Rice Buys 17,822 Shares of Aptose Biosciences Inc. (NASDAQ:APTO) Stock  2021/12/16 15:22:41 Dakota Financial News
Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) CEO William G. Rice bought 17,822 shares of Aptose Biosciences stock in a transaction that occurred on Wednesday, December 15th. The stock was bought at an average price of $1.12 per share, with a total value of $19,960.64. The acquisition was disclosed in a legal filing with the SEC, which []
   Aptose Biosciences (APS) Buy Rating Reiterated at HC Wainwright  2021/12/16 06:48:42 Dakota Financial News
HC Wainwright reissued their buy rating on shares of Aptose Biosciences (TSE:APS) (NASDAQ:APTO) in a report issued on Tuesday, TipRanks reports. The brokerage currently has a C$14.00 price objective on the biotechnology companys stock. Separately, Cantor Fitzgerald reaffirmed an overweight rating on shares of Aptose Biosciences in a research report on Wednesday, November 17th. TSE:APS []

calendar